☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Guselkumab
PharmaShots Interview: Janssen’s Soumya D. Chakravarty Shares Insights on Tremfya (guselkumab) for the Treatment of Active Psoriat...
April 25, 2022
PharmaShots Interview: Dr. Philip Mease Shares Insights on the Clinical data of Tremfya (guselkumab) Presented in The Lancet Rheum...
September 22, 2021
Janssen Reports Results of Tremfya (guselkumab) in Interim Analysis of P-II GALAXI 1 Study for Moderately to Severely Active Crohn...
October 12, 2020
Janssen's Tremfya (guselkumab) Receives the US FDA's Approval as the First Selective IL-23 Inhibitor for Active Psoriatic Arthriti...
September 11, 2020
Load more...
Back to Home
Modal title
×
Modal body text goes here.